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Abstract
Background: Polycomb group (PcG) genes code for chromatin multiprotein complexes that are responsible for
maintaining gene silencing of transcriptional programs during differentiation and in adult tissues. Despite the large
amount of information on PcG function during development and cell identity homeostasis, little is known
regarding the dynamics of PcG complexes and their role during terminal differentiation.
Results: We show that two distinct polycomb repressive complex (PRC)2 complexes contribute to skeletal muscle
cell differentiation: the PRC2-Ezh2 complex, which is bound to the myogenin (MyoG) promoter and muscle creatine
kinase (mCK) enhancer in proliferating myoblasts, and the PRC2-Ezh1 complex, which replaces PRC2-Ezh2 on MyoG
promoter in post-mitotic myotubes. Interestingly, the opposing dynamics of PRC2-Ezh2 and PRC2-Ezh1 at these
muscle regulatory regions is differentially regulated at the chromatin level by Msk1 dependent methyl/phospho
switch mechanism involving phosphorylation of serine 28 of the H3 histone (H3S28ph). While Msk1/H3S28ph is
critical for the displacement of the PRC2-Ezh2 complex, this pathway does not influence the binding of PRC2-Ezh1
on the chromatin. Importantly, depletion of Ezh1 impairs muscle differentiation and the chromatin recruitment of
MyoD to the MyoG promoter in differentiating myotubes. We propose that PRC2-Ezh1 is necessary for controlling
the proper timing of MyoG transcriptional activation and thus, in contrast to PRC2-Ezh2, is required for myogenic
differentiation.
Conclusions: Our data reveal another important layer of epigenetic control orchestrating skeletal muscle cell
terminal differentiation, and introduce a novel function of the PRC2-Ezh1 complex in promoter setting.
Background
During development, differentiation programs require
global rearrangements in repression and activation of
lineage-specific genes. Chromatin-based epigenetic
mechanisms ensure correct integration of developmental
signals at gene regulatory regions, allowing the action of
transcription factors and maintaining novel expression
states in derived cell populations. Polycomb group
(PcG) proteins are transcriptional repressors that remo-
del chromatin through epigenetic modifications that
prevent changes in cell identity by maintaining tran-
scription patterns, throughout development and in
adulthood [1,2]. They comprise two major multiprotein
complexes, polycomb repressive complex (PRC)-1 and
PRC-2. PRC1 is the larger-sized complex that contains
several polypeptides whose functions include ubiquitina-
tion of histone H2A at lysine 119 (H2AK119), chroma-
tin compaction and regulation of the basal transcription
machinery [3]. The core of the PRC2 complex is made
up of three proteins, Suz12, Eed and Ezh2, the latter
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being the catalytic subunit that modifies histone H3 by
trimethylation of lysine 27 (H3K27me3). Once
H3K27me3 has been established, PRC2 is able to bind
to this mark via the Eed subunit, which in turn activates
the histone methyltransferase activity (HMT) of the
complex [4,5]. This process allows maintenance of the
repressive mark and its transmission to daughter cells
[6]. Recently, it has been reported that in mammals
HMTase Ezh2 can be replaced by another highly homo-
logous polypeptide called Ezh1. However, whereas
PRC2-Ezh2 catalyses H3K27me2/me3 and its knock-
down affects global H3K27me2/me3 levels, PRC2-Ezh1
performs this function weakly [7,8]. Although Ezh1
depletion does not impact global H3K27me2/me3 levels,
the PRC2-Ezh1 complex robustly represses transcription
from chromatinised templates and compact chromatin
[7]. Interestingly, while Ezh2 expression is closely asso-
ciated with proliferation, Ezh1 is more abundant in non-
proliferative adult organs, suggesting that these two
PRC2 complexes may have different functions in divid-
ing versus post-mitotic cells [9,10]. Thus, replacement
of the Ezh2 subunit with Ezh1 appears to be develop-
mentally regulated. To date, however, the function of
Ezh1 in differentiating cells remains elusive.
Vertebrate skeletal muscle formation constitutes an
interesting model system to study the epigenetic signals
and molecular mechanisms that govern cellular differen-
tiation [11,12]. Previous work revealed a crucial role of
Ezh2 in skeletal muscle cell differentiation as its tran-
scriptional and post-transcriptional downregulation is
required to allow activation of muscle-specific genes
[13,14]. During myogenic differentiation, extracellular
signals are transduced into the nucleus by mitogen-acti-
vated protein kinases (MAPKs), p38 or extracellular sig-
nal-regulated kinase (ERK) [15,16]. The mitogen- and
stress-activated protein kinases (Msk-1 and Msk-2),
downstream targets of the p38 or ERK pathways [17],
are responsible for the histone H3 phosphorylation at
serine 28 (H3S28ph) and serine 10 (H3S10ph) [18,19].
Recent data show that an H3K27/H3S28 methyl/phos-
pho switch mechanism regulates gene activation via
PRC2 chromatin displacement during neuronal differen-
tiation, stress response and mitogenic signalling [20,21].
If a similar mechanism is involved in muscle gene acti-
vation, allowing for PcG chromatin displacement,
remains to be elucidated.
In the current work we report that two different PRC2
complexes contribute to skeletal muscle differentiation:
PRC2-Ezh2, which is predominant in proliferating myo-
blasts, and PRC2-Ezh1, which contains Ezh1 but is
devoid of Ezh2, and is specific for post-mitotic myo-
tubes. Interestingly, these two PRC2 complexes are dif-
ferentially associated with muscle regulatory regions.
Indeed, while muscle creatine kinase (mCK) is a classic
PRC2 target gene where its expression is associated with
the displacement of PRC2-Ezh2 complex, myogenin
(MyoG) shows a switch between PRC2-Ezh2/PRC2-Ezh1
complexes upon differentiation, suggesting a role of this
dynamics in gene activation. In light of their different
chromatin associations, we verified that a Msk1-depen-
dent signalling that controls H3S28ph, is involved in the
specific displacement of PRC2-Ezh2 from the MyoG and
mCK regulatory regions, to result in muscle differentia-
tion. This confirms the findings of previous reports that
consider Ezh2 downregulation to be a necessary step in
the myoblast-myotube transition [13,14]. Surprisingly,
we found that the PRC2-Ezh1 complex is insensitive to
the H3S28ph activation mark. Indeed, this complex reg-
ulates the proper timing of MyoG transcriptional activa-
tion via recruitment of MyoD transcriptional factor in
post-mitotic myotubes.
Thus, our study reveals a novel important layer of
PcG-mediated epigenetic regulation of skeletal muscle
cell differentiation, in which the different dynamics and
chromatin regulated switch between PRC2-Ezh2 and
PRC2-Ezh1 complexes are coordinated to induce the
transition from myoblast to myotube transcriptional
programs.
Results
Two PRC2 complexes, PRC2-Ezh2 and PRC2-Ezh1, are
present during myogenic differentiation
It is known that decreasing levels of PcG Ezh2 protein
activates the terminal myogenic program at the time of
differentiation, thereby controlling skeletal muscle gene
regulation [13,14]. However, the functions of other
PRC2 components during the critical time of myoblast
to myotube transition are not known. We sought to
investigate the dynamics of PRC2 components during
skeletal muscle differentiation of the C2C12 cell line. In
this system, the replacement of growth medium (GM)
by differentiation medium (DM) induces proliferative
myoblasts to exit the cell cycle, to express muscle-speci-
fic genes, such as MyoG, mCK and myosin heavy chain
IIB (MHCIIB), and subsequently to fuse into multinu-
cleated terminally differentiated myotubes [22] (Figure
1A). Ezh2 protein was efficiently downregulated in dif-
ferentiated cells (48 and 72 h after differentiation induc-
tion, Figure 1B), as previously reported [13,14], while
Suz12 and Eed were still present in myotubes, although
at lower levels. Curiously, Ezh1 levels remained constant
throughout differentiation. A similar profile was
obtained analysing the mRNA levels of these PRC2
components (Figure 1C). We performed the same analy-
sis in human primary myoblasts triggered to differenti-
ate into myotubes over the course of 8 days and in
primary satellite cells isolated from adult mice. In these
cells the pattern of PRC2 components was similar to
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that obtained in C2C12 cells, suggesting that the
observed PRC2 dynamics is indeed a feature of skeletal
muscle differentiation (Additional file 1). To investigate
the composition of the PRC2 complex, we carried out
size exclusion chromatography analyses of nuclear
extracts from undifferentiated and differentiated C2C12
cells, followed by immunoblot of the eluted fractions for
Ezh2, Suz12, Eed and Ezh1 components. The results
showed that the majority of the four PRC2 proteins
were eluted in a 700 kDa fraction (fraction 12-13) in
both myoblasts and myotubes (Figure 1D, I), corre-
sponding to the molecular weight of the PRC2 complex
A B
D I)
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Figure 1 Dynamics of PRC2-Ezh2 and PRC2-Ezh1 complexes during C2C12 skeletal muscle cell differentiation. (A) Schematic
representation of C2C12 skeletal muscle cell differentiation. Proliferative myoblasts at 80% confluency were induced to differentiate for 24-72 h
by replacing growth medium (GM) with differentiating medium (DM). (B) Immunoblot of Ezh2, Ezh1, Suz12 and Eed from whole cell extracts of
cells cultured as myoblasts in GM (prol = proliferative myoblasts at 50% confluence; conf = 80% confluent myoblasts) or as myotubes in DM (24
h, 48 h and 72 h after differentiation induction). Myogenin and myosin heavy chain IIB (MHCIIB) were used as muscle differentiation controls for
the early and late stages of differentiation, respectively. b-Tubulin was used as a loading control. Asterisk indicates EZH1 unspecific band.
Different bands of Eed represent the isoforms of this protein. (C) Expression levels of Ezh2, Ezh1, Suz12 and Eed were measured by real-time PCR
in myoblasts grown in GM or DM, for 24 h, 48 h or 72 h after induction of differentiation. MHCIIB was used as a muscle differentiation control.
The transcription levels were normalised to Gapdh expression and represent the mean of three independent experiments ± SD. Fold enrichment
was calculated in comparison to myoblasts in GM. (D) (I) Size exclusion chromatography of nuclear extracts prepared from myoblasts in GM (left
panel) or DM (72 h after differentiation induction) (right panel) showing coelution of Ezh2, Suz12, Eed and Ezh1 in high molecular weight
fractions. The indicated fractions were analysed by immunoblot. (II) Ezh2 was immunodepleted from extracts prepared from cells cultured in DM
(72 h after differentiation induction) and nuclear extract were analysed as described in (I).
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[23]. Since Ezh2 is degraded in myotubes (Figure 1B),
we tested the possibility that an alternative PRC2 com-
plex, formed by Suz12, Eed and Ezh1 and independent
of Ezh2, could exist in post-mitotic cells. We therefore
repeated the experiment using Ezh2 immunodepleted
myotube extracts (Figure 1D, II). Interestingly, Suz12,
Eed and Ezh1 subunits still coeluted at the same mole-
cular weight. Taken together, these data suggest the
existence of at least two PRC2 complexes in skeletal
muscle cells, PRC2-Ezh2, predominant in proliferative
myoblasts, and PRC2-Ezh1, more abundant in post-
mitotic myotubes.
PRC2-Ezh2 and PRC2-Ezh1 complexes are differentially
associated with muscle gene regulatory regions
We then investigated the dynamics of the binding of
PRC2-Ezh2 and PRC2-Ezh1 complexes to their targets,
the MyoG promoter and mCK enhancer [13,14]. C2C12
cells were triggered to differentiate in low serum condi-
tions over the course of 8 days, and chromatin immuno-
precipitation (ChIP) experiments were performed before
and after differentiation with antibodies against Ezh2,
Suz12, Ezh1 and RNA polymerase II (RNA Pol II). This
extended timecourse allowed us to observe the differences
in the expression profiles of these two muscle-specific
genes, MyoG and mCK. Indeed, MyoG was expressed in
myocytes at day 2; levels peaked at day 4 and decreased at
day 8, after fusion into polynucleated myotubes [24,25]
(Figure 2A, I); in contrast, mCK levels increased through-
out C2C12 differentiation [22] (Figure 2B, I). Ezh2 and
Suz12 proteins (components of the PRC2-Ezh2 complex)
were detected both on the MyoG promoter and mCK
enhancer in undifferentiated myoblasts (Figure 2A, II and
2B, II). Although Suz12 remained bound to the MyoG pro-
moter, Ezh1 replaced Ezh2 (PRC2-Ezh1) upon differentia-
tion (DM day 2) (Figure 2A, II). These events correlated
with RNA Pol II recruitment (Figure 2A, III). However,
the levels of the binding of PRC2-Ezh1 and RNA Pol II at
the MyoG promoter were inversely correlated during later
stages of differentiation (DM days 4 and 8) (Figure 2A, II
and 2III). Of note, we did not detect the PRC2-Ezh1 com-
plex on the mCK enhancer in differentiating C2C12 cells
(Figure 2B, II), whereas the recruitment of RNA Pol II
progressively increased (Figure 2B, III).
Taken together, these results suggest that the binding
of the PRC2-Ezh1 complex at the MyoG promoter in
differentiating cells could play a role in the regulation of
the proper transcriptional profile of this gene.
A H3K27/H3S28 methyl/phospho switch regulates muscle
gene activation via PRC2-Ezh2 chromatin displacement
Muscle gene activation requires the concerted recruit-
ment of chromatin remodelling complexes, such as
SWItch/Sucrose Non-Fermentable (SWI/SNF) [15] and
the displacement of the PRC2-Ezh2 complex [13]. Our
data, by showing that the PRC2-Ezh1 complex associates
with the MyoG promoter, suggests evidence for an
unexpected scenario in which signal-dependent changes
in chromatin have to deal with two different PRC2 com-
plexes. We decided to test the possibility that the pre-
viously reported H3K27/H3S28 methyl/phospho switch
mechanism [20,21] could act at this level to regulate the
PRC2-Ezh2 displacement during myogenic differentia-
tion. We therefore analysed the binding of Msk1 and
Ezh2 and their associated histone marks (H3S28ph and
H3K27me3, respectively) at MyoG and mCK regulatory
regions. Concomitant with the activation of these two
genes, levels of H3S28ph and another active mark,
acetylated histone 3 (AcH3), peaked at the MyoG pro-
moter (Figure 3A) and mCK enhancer and promoter
(Figure 3B, C) in myotubes. Enrichment of H3S28ph at
these regions was associated with recruitment of Msk1
kinase (Figure 3A-C). Interestingly, in myotubes, an
increase in H3S28ph correlated with the displacement
of the PRC2-Ezh2 complex and the retention of
H3K27me3 at MyoG (Figure 3A) and mCK promoter
regions (Figure 3C). In contrast, at the mCK enhancer,
loss of the PRC2-Ezh2 complex occurred simultaneously
with H3S28ph enrichment and decrease in H3K27me3
during muscle differentiation (Figure 3B). Additionally,
we analysed cells treated with H89, a compound known
to inhibit Msk1 kinase activity [18,20,26]. Although H89
has been used at concentrations as high as 20 μM
[18,27], lower doses (for example, 5 μM and 10 μM)
were shown to inhibit Msk1 kinase more specifically
[20,28]. Treatment with H89 impaired the establishment
of the H3S28ph mark, the AcH3 mark and the recruit-
ment of Msk1 kinase at MyoG promoter (Figure 3A),
mCK enhancer (Figure 3B) and mCK promoter (Figure
3C) as well as activation of these genes (Additional file
2A-D). These events were accompanied by retention of
PRC2-Ezh2 only at MyoG (Figure 3A) and mCK promo-
ter regions (Figure 3C). In contrast, at mCK enhancer
we did not detect PRC2-Ezh2 chromatin retention after
H89 treatment (Figure 3B). The differences in Ezh2
binding between these two mCK regulatory regions and
MyoG promoter could be explained by different degrees
in H3K27me3 levels, in that this repressive mark
increased upon H89 treatment at the MyoG (Figure 3A)
and mCK promoters (Figure 3C) but not at the mCK
enhancer (Figure 3B). Thus, the loss of the docking site
H3K27me3 on the mCK enhancer could be sufficient to
determine PRC2-Ezh2 chromatin displacement.
In light of the known role that Msk1 plays in the phos-
phorylation of H3S10 [18], we asked whether H3S10ph
was also involved in muscle gene activation. However,
because we did not observe any increase of this modifica-
tion at the MyoG and mCK regulatory regions during
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muscle differentiation, we ruled out the possibility that
H3S10ph functions in muscle gene activation (Additional
file 2E). Furthermore, we examined whether Msk1 can
phosphorylate H3S28 in an environment including pre-
existing H3K27me3. Recombinant Msk1 kinase was incu-
bated with a histone H3 (residues 21-33) peptide, which
was either unmodified or modified with K27me3 or
S28ph. Although the H3K27me3 substrate was
phosphorylated under similar kinetic conditions as the
unmodified peptide, no phosphorylation of the H3S28ph
substrate was observed (Figure 3D), indicating that the
serine 28 is the only residue phosphorylated by Msk1.
Taken together, these data suggest that displacement of
the PRC2-Ezh2 complex from MyoG and mCK promoters
is regulated by a H3K27me3/H3S28ph switch via Msk1
recruitment onto chromatin.
Figure 2 Myogenin (MyoG) and muscle creatine kinase (mCK) muscle markers are differentially bound by PRC2-Ezh2 and PRC2-Ezh1
complexes in C2C12 cell lines. (A) (I) Expression levels of MyoG were measured by real-time PCR in myoblasts grown in growth medium (GM)
or differentiation medium (DM), 2, 4 or 8 days after induction of differentiation. The transcription levels were normalised to Gapdh expression
and represent the mean of three independent experiments ± SD. Fold enrichment was calculated in comparison to myoblasts in GM. (II, III)
Chromatin immunoprecipitation (ChIP) analysis of chromatin prepared from cells cultured in GM or in DM for 2, 4 and 8 days with Ezh2, Suz12,
Ezh1 (II) and RNA polymerase II (RNA Pol II) (III) antibodies. The precipitated DNA fragments were subjected to real-time PCR analysis using
primers designed within MyoG promoter. ChIP enrichments are presented as a percentage (%) of the input. Data are shown as an average of
three independent experiments ± SD. (B) (I) Expression levels of mCK were measured by real-time PCR in myoblasts grown in GM or DM, 2, 4,
or 8 days after induction of differentiation. The transcription levels were normalised to Gapdh expression and represent the mean of three
independent experiments ± SD. Fold enrichment was calculated in comparison to myoblasts in GM. (II, III) ChIP analysis of chromatin prepared
from cells cultured in GM or in DM for 2, 4 and 8 days with Ezh2, Suz12, Ezh1 (II) and RNA Pol II (III) antibodies. The precipitated DNA fragments
were subjected to real-time PCR analysis using primers designed within mCK enhancer. ChIP enrichments are presented as percentage of the
input. Data are shown as average of three independent experiments ± SD.
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Figure 3 Msk1-dependent H3S28 phosphorylation affects PRC2-Ezh2 chromatin displacement from muscle regulatory regions.
Chromatin immunoprecipitation (ChIP) analysis was performed on chromatin prepared from C2C12 cells cultured in growth medium (GM) or
differentiation medium (DM) 48 h after induction of differentiation with or without Msk1 inhibitor H89 (5 μM) using histone H3 phosphorylation at
serine 28 (H3S28ph), acetylated histone 3 (AcH3), Msk1, Ezh2 and H3K27me3 antibodies. The precipitated DNA fragments were subjected to real-
time PCR analysis with primers amplifying the myogenin (MyoG) promoter (A), muscle creatine kinase (mCK) enhancer (B) and mCK promoter (C).
ChIP values are presented as relative enrichments to myoblasts. Levels of H3S28ph, AcH3 and H3K27me3 were normalised to histone H3 density.
Data represent the average of three independent experiments. Error bars represent SD. (D) Recombinant Msk1 was incubated with a histone H3
(residues 21-33) peptide either unmodified or modified with the K27me3 or S28ph, and a kinase assay was performed (cpm = counts per min).
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PRC2-Ezh2 and PRC2-Ezh1 chromatin dynamics are
differentially regulated by a H3K27/H3S28 methyl/
phospho switch
In order to provide direct mechanistic evidence for the
involvement of the H3S28ph mark in the PRC2-Ezh2
chromatin displacement, we performed affinity-purifica-
tion experiments using long histone H3 (residues 1-40)
tail peptides, unmodified or modified with K27me3 or
modified with the double mark K27me3S28ph, and we
incubated them with nuclear extracts prepared from
C2C12 myoblasts and myotubes. In agreement with ear-
lier findings [4,6], Ezh2, Suz12 and Eed bound the
H3K27me3 peptide (Figure 4A). Interestingly, interac-
tion of all three PRC2 core components with the
H3K27me3 docking site was significantly weakened in
the presence of neighbouring H3S28ph (Figure 4A). The
similar trend was observed when extracts prepared from
undifferentiated myoblasts as well as from differentiated
myotubes were used (Figure 4A). We therefore conclude
that the ability of the PRC2-Ezh2 complex to bind
H3K27me3 and to show sensitivity to H3S28ph is inher-
ent to the complex, and is independent of differentia-
tion. Since we observed that Ezh1 binding on the MyoG
promoter upon differentiation (Figure 2A, II) occurs
together with H3S28ph (Figure 3A), we next asked
whether Ezh1 is retained on H3K27me3 even in the
presence of the adjacent phosphorylated site. Compar-
able amounts of Ezh1 were bound to H3K27me3 and
H3K27me3S28ph peptides from extracts of differen-
tiated myotubes (Figure 4B). We conclude that Msk1-
mediated phosphorylation of H3S28 impairs PRC2-Ezh2,
but not PRC2-Ezh1 binding to its docking site,
H3K27me3.
Correct timing of myogenin transcriptional activation
requires the PRC2-Ezh1 complex
Our data show that the PRC2-Ezh1 complex is bound at
the MyoG promoter upon gene activation (Figure 2A)
and it is retained on H3K27me3 even in the presence of
H3S28ph (Figure 4B). For these reasons, we explored
the role of Ezh1 in MyoG regulation. We performed
loss-of-function experiments in which C2C12 myoblasts
were transiently transfected with two different small
interfering RNAs (siRNAs) targeting Ezh1, and induced
to differentiate for 48 h (Figure 5A), the temporal win-
dow in which MyoG is activated. As shown by phase
contrast microscopy, Ezh1-depleted cells were not able
to correctly differentiate (Figure 5B, central panels),
while Ezh2-depleted cells differentiated normally in
agreement with previously published data (Figure 5B,
right panel) [13]. The efficiency of knockdown experi-
ments is shown in Additional file 3. Ezh1-depleted cells
displayed a delay in transcriptional activation of MyoG
but not mCK (Figure 5C, left panels), while Ezh2-
depleted cells did not show any decrease in MyoG and
mCK expression (Figure 5C, right panels). The impair-
ment in MyoG expression in Ezh1-depleted C2C12 cells
was also confirmed at protein level (Figure 5D). Notably,
a delay of MyoG transcriptional activation was also
found in Ezh1-depleted human myoblasts and satellite
cells (Additional file 4). In order to rule out the possibi-
lity that the muscle differentiation delay was due to an
inability to switch off proliferation programs, we ana-
lysed the proliferative capability of C2C12 cells after
Ezh1 knockdown. Ezh1-depleted myoblasts exhibited the
same growth curve as the negative control (Figure 5E).
Furthermore, p21 and cyclin D1 mRNA levels were not
significantly affected either in Ezh1-depleted or in Ezh2-
depleted cells (Figure 5F). Since Ezh1 was found in a
complex with Suz12 and Eed in myotubes (Figure 1D,
II), we performed the same knockdown approach target-
ing Suz12 in C2C12 cells (Figure 6), human myoblasts
and satellite cells (Additional file 5). As revealed by
phase contrast microscopy (Figure 6A Additional file
5A, C), a delay of muscle differentiation was detected
after Suz12 depletion in each system, a result which was
confirmed by lower protein (Figure 6B) and mRNA
levels of MyoG and mCK muscle markers (Figure 6C
Additional file 5B). In contrast to Ezh1 knockdown cells,
the proliferation capability of Suz12-depleted C2C12
A
B
Figure 4 H3K27me3/H3S28ph switch specifically influences the
chromatin binding of the PRC2-Ezh2 complex but not PRC2-
Ezh1. (A) Nuclear extracts from C2C12 myoblasts (growth medium
(GM)) and myotubes (differentiation medium (DM), 48 h after
differentiation induction) were incubated with peptides representing
unmodified H3, K27me3-H3 or the double modification
K27me3S28ph-H3. Binding of Ezh2, Suz12 and Eed was tested by
immunoblot. (B) Nuclear extracts from C2C12 cells cultured in DM,
48 h after induction of differentiation, were incubated with the
same peptides as those listed in (A) and the binding of Ezh2 and
Ezh1 was tested by immunoblot.
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Figure 5 Ezh1-depleted C2C12 cells show a delay of myogenin (MyoG) transcriptional activation. (A) Schematic representation of the
design of small interfering RNA (siRNA) knockdown experiments used in this study. (B) Myoblasts were transfected with non-targeting siRNA (Nc
= negative control) or siRNA against Ezh1 and Ezh2. The effect of siRNA on cell morphology was analysed in growth medium (GM) (48 h after
transfection) and in differentiation medium (DM) (48 h after differentiation induction) by phase-contrast microscopy. A single siRNA for Ezh2,
representative of two different siRNAs, is shown. (C) Expression levels of MyoG and muscle creatine kinase (mCK) muscle markers were analysed
by real-time PCR in GM and in DM. Transcription levels were normalised to Gapdh expression and represented as the average of three
independent experiments ± SD. Fold enrichment was calculated in comparison to the negative control siRNA in GM. (D) Ezh1-depletion was
performed as described in (A) and MyoG protein levels were analysed using whole cell extracts prepared from cells cultured in GM and DM,
respectively. b-Tubulin served as a loading control. (E) Effect of Ezh1 depletion on cell proliferation. The cells were counted 24 h, 48 h, 72 h and
96 h after siRNA transfection. Ezh1 siRNA oligo no. 2 was used. Graph shows data from two independent experiments. Error bars represent the
standard deviation (Nc = negative control). (F) Expression levels of p21 and cyclin D1 genes were analysed by real-time PCR in GM and in DM
(24 h and 48 h after differentiation induction). The transcription levels were normalised to Gapdh expression and represented as the average of
three independent experiments ± SD. Fold enrichment was calculated in comparison to the negative control siRNA in GM.
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cells was impaired (Figure 6D). Indeed, flow cytometric
analysis of the cell cycle revealed an accumulation of the
cells in G1/S phase after only 48 h of treatment with
Suz12 siRNA (Figure 6E), whereas the amount of
apoptotic cells was comparable to the control cells (data
not shown). These results, consistent with previously
reported studies [29], may be explained by an autono-
mous cell cycle defect induced by the specific
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Figure 6 Suz12 small interfering RNA (siRNA) impairs proliferation and differentiation in C2C12 cell lines. (A) Myoblasts were transfected with
non-targeting siRNA (Nc = negative control) or siRNA against Suz12. The effect of siRNA on cell morphology was analysed in growth medium (GM) (48
h after transfection) and in differentiation medium (DM) (48 h after differentiation induction) by phase-contrast microscopy. (B) Immunoblot of Suz12,
myogenin (MyoG) and muscle creatine kinase (mCK) was performed after Suz12 depletion (oligo no. 1) using the experimental design described in
Figure 5A and the protein levels were analysed in cells cultured in GM and in DM (48 h after differentiation induction), respectively. Nuclear (NE) and
cytosolic (CE) extracts were used for the analysis, with b-tubulin serving as a cytosolic and Drosha as a nuclear extract control. (C) The efficiency of
Suz12 siRNA and the expression levels of MyoG and mCK were tested by real-time PCR in GM and in DM (48 h after differentiation induction) in Suz12-
depleted cells. The transcription levels were normalised to Gapdh expression and represented as the average of three independent experiments ± SD.
Fold enrichment was calculated in comparison to the negative control siRNA in GM. (D) Effect of Suz12 depletion on cell proliferation. The cells were
counted 24 h, 48 h, 72 h and 96 h after siRNA transfection. Suz12 siRNA oligo no. 1 was used. Graph shows data from three independent experiments.
Error bars represent the standard deviation (Nc = negative control). (E) Cell cycle profiles were analysed by fluorescence-activated cell sorting (FACS)
after Suz12 siRNA delivery at the same time timepoints as in (D). P4 gate represents G1 phase, P5 represents S phase and P6 represents G2 phase.
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derepression of PRC2 target genes such as cytokines
[30,31]. To further support the putative role of Ezh1 in
controlling muscle differentiation, we compared the pro-
tein levels of the three PRC2 components, Ezh1, Ezh2 and
Suz12, in each C2C12 siRNA experiment (Figure 7A).
Interestingly, depletion of Suz12 resulted in the loss of
both Ezh1 and Ezh2 proteins in myoblasts and myotubes
(Figure 7A, I and 7II). Conversely, in Ezh2-depleted cells,
we observed lower Suz12 and higher Ezh1 protein levels
both in myoblasts and in myotubes (Figure 7A, II and 7III)
while in Ezh1-depleted cells, we did not observe any
change in Suz12 and Ezh2 protein levels (Figure 7A, IV).
The results are summarised in Figure 7A, V: the loss of
Ezh1 represents the only common factor in cells that were
not able to differentiate (Suz12-depleted and Ezh1-
depleted C2C12 cells). Indeed, cells that differentiate nor-
mally (Ezh2-depleted C2C12 cells) showed higher levels of
Ezh1. In contrast, the levels of Suz12 and Ezh2 changed
independently of the differentiation ability of the cells. The
same results were obtained with a different experimental
A
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I) II)
III) IV)
C
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DM-2d
DM-4d
hMYOGENIN
hSUZ12hEZH1
hEZH2
V)
Figure 7 Ezh1 is the unique PRC2 component required for skeletal muscle differentiation. (A) Immunoblot analysis of Ezh1, Suz12 and
Ezh2 levels in whole cell extracts prepared from C2C12 myoblasts cultured in growth medium (GM) and differentiation medium (DM), 48 h after
differentiation induction, in Suz12-depleted (I, II), Ezh2-depleted (II, III) and Ezh1-depleted (III, IV) cells. b-Tubulin served as a loading control. (V)
Schematic representation of the muscle differentiation phenotypes detected after downregulation of single PRC2 components (Suz12, Ezh1 and
Ezh2) and the impact on the protein levels of the remaining members of the complex. PRC2 reciprocal levels: - indicates that protein levels
decline; – indicates that protein levels strongly decline; + indicates that protein levels increase; ++ indicates that protein levels strongly increase.
Myogenic differentiation: - indicates a delay in muscle differentiation; ++ indicates an acceleration of muscle differentiation. Phenotypes showing
a delay in muscle differentiation are highlighted in grey, while phenotypes showing acceleration are in black. (B) Human myoblasts were
transfected with non-targeting small interfering RNA (siRNA) (Nc = negative control) or siRNAs against Ezh1-Suz12 and Ezh2-Suz12. The effect of
protein downregulation on cell morphology was analysed in GM (48 h after transfection) and in DM (2 and 4 days after differentiation induction)
by phase-contrast microscopy. (C) The efficiency of each siRNA and the expression levels of myogenin (MyoG) were tested by real-time PCR in
GM and in DM (2 days and 4 days after differentiation induction) in human myoblasts depleted for specific PRC2 components, as described in
(B). The transcription levels were normalised to Gapdh expression and represented as the average of three independent experiments ± SD. Fold
enrichment was calculated in comparison to the negative control siRNA in GM.
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approach (Figure 7B, C). Human primary myoblasts were
depleted for both Ezh1/Suz12 (PRC2-Ezh1 complex) or
Ezh2/Suz12 (PRC2-Ezh2 complex) proteins. The depletion
of both Ezh1 and Suz12 proteins impaired myogenic dif-
ferentiation (Figure 7B). Indeed, lower MyoG mRNA
levels were detected at 2 and 4 days after myogenic induc-
tion (Figure 7C). Conversely, cells depleted of both Suz12
and Ezh2 did not show any change in their differentiation
ability (Figure 7B) and normal mRNA levels of MyoG
were detected (Figure 7C). Thus, the process of myogenic
differentiation is linked to the presence of Ezh1 or Ezh2
proteins, the components that distinguish PRC2-Ezh1 and
PRC2-Ezh2 complexes.
PRC2-Ezh1 is required for the recruitment of MyoD on
myogenin promoter
Ezh1-depleted cells showed strong defects in the proper
timing of myogenin transcriptional activation (Figure 5C),
an event required for the initiation of myogenic differen-
tiation. Since the MyoD transcription factor is considered
one of the key elements involved in the MyoG activation
process [32,33], we wondered if Ezh1 depletion could
impair MyoD recruitment on the MyoG gene. Upon differ-
entiation induction, lower levels of MyoD were detected in
Ezh1-depleted myotubes (Figure 8A, left panel). The oppo-
site effect was observed after Ezh2 knockdown (Figure 8A,
left panel). Interestingly, we did not detect any decrease in
MyoD binding at the mCK enhancer, for both the Ezh1-
depleted and Ezh2-depleted cells (Figure 8A, right panel),
suggesting that the delay in MyoG transcriptional activa-
tion could be a direct consequence of the impairment of
MyoD recruitment at this particular gene. Moreover, after
Ezh1 and Ezh2 depletion, we analysed the recruitment of
RNA Pol II and the occurrence of active chromatin mark
H3K4me3 on the MyoG promoter as well as on three dif-
ferent regions along the coding sequence of this gene (A,
B and C). The binding of RNA Pol II was reduced at the
coding region A, but not at the promoter, in the Ezh1 but
not the Ezh2 knockdown (Figure 8B, upper panel), sug-
gesting an impairment in the elongation step of the tran-
scriptional process. Furthermore, only Ezh1-depleted cells
displayed a reduction in the H3K4me3 active mark along
the coding regions of MyoG (Figure 8B, lower panel).
Taken together, these data demonstrate the importance of
the role of the PRC2-Ezh1 complex in the correct timing
of MyoG transcriptional activation through proper recruit-
ment of MyoD on the MyoG promoter.
Discussion
Different dynamics of PRC2-Ezh2 and PRC2-Ezh1
complexes allow the correct timing of skeletal muscle
gene transcriptional activation
PcG proteins contribute to differentiation through their
ability to repress transcription of developmental
regulators in committed cells, including skeletal muscle
cell lines. Previous analysis of Ezh2 dynamics during
myogenic differentiation has lead to a two-step activa-
tion model defining PcG-dependent muscle gene expres-
sion and cell differentiation [13]. However, a broad
analysis of other PRC2 core components (Suz12 and
Eed), including Ezh1, has not yet been attempted. Our
data show that Ezh1 is the only PRC2 component that
is maintained at constant levels during myogenic differ-
entiation, while levels of Ezh2, Suz12 and Eed, to differ-
ent extent, decrease from undifferentiated to
differentiated states (Figure 1B, C and Additional file 1).
We propose that skeletal muscle differentiation could be
regulated by two distinct PRC2 complexes, PRC2-Ezh2
in myoblasts and PRC2-Ezh1 in myotubes. Existence of
two partially redundant PRC2 complexes has been pre-
viously reported [7-10]. However, our data suggest that
Ezh1 is more than just a substitute for Ezh2. Indeed,
observations regarding the chromatin dynamics of the
PRC2-Ezh1 complex on the MyoG promoter raise ques-
tions as to its functionality during skeletal muscle cell
differentiation. Insight regarding the function of Ezh1 in
skeletal muscle differentiation can be derived from the
evidence that, unlike Ezh2 [13], Ezh1 is required for
myogenic differentiation (Figure 5). In regard to this, we
detected Ezh1 on the MyoG promoter when the gene is
activated and RNA Pol II is recruited (Figure 2A).
Indeed, Ezh1 depletion led to a delay of MyoG tran-
scriptional activation due to the impairment of MyoD
recruitment on the MyoG promoter (Figure 8). How-
ever, at the later stages of differentiation, the binding of
Ezh1 and Suz12 (Figure 2A) could indicate that this
complex has a role in the subsequent resilencing of
MyoG in terminally differentiated myotubes. In agree-
ment with this hypothesis, a recent report showed that
MyoG upregulation during the initial stages of skeletal
muscle differentiation is followed by subsequent repres-
sion [34]. Notably, MyoG is activated in the early stages
of neurogenic muscle atrophy and failure in later down-
regulation is causally correlated with disease progression
[35].
Surprisingly, our data showed that a PcG protein, such
as Ezh1, is recruited on muscle specific gene when it is
activated. Indeed, previous reports provided evidences
that other PcG proteins bind actively transcribed genes
[36,37]. The coexistence of active (AcH3, H3S28ph and
H3K4me3) and repressive marks (H3K27me3) at the
MyoG promoter could be similar to the bivalent
domains of embryonic stem (ES) cells, as it has been
shown that these domains are not limited to these cells
[38]. Indeed, 10% to 20% of reported PcG target genes
in ES cells are transcriptionally active [31,39]. The pre-
sence of PcG on active genes may be comparable to the
presence of trithorax (trxG) proteins on repressed genes
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as this dual configuration of PcG and trxG proteins on
active and repressed regions may provide a given gene
with the flexibility to rapidly change its expression pro-
file upon developmental or environmental stimuli.
As Ezh1 methyltransferase activity on histones is
found to be modest [7], it will be interesting to investi-
gate whether this PcG protein has targets in addition to
histone H3, such as RNA Pol II enzyme. Indeed, a very
recent report reveals that the C-terminal domain (CTD)
of RNA Pol II is methylated by the coactivator-asso-
ciated arginine methyltransferase 1 (CARM1) [40].
Future genome-wide analysis coupled to loss-of-func-
tion experiments will be required to address EZH1 func-
tion in myofibres.
B
A
Figure 8 Myogenin (MyoG) transcriptional activation, via recruitment of MyoD, is regulated by the PRC2-Ezh1 complex. Chromatin
immunoprecipitation (ChIP) analysis was performed using chromatin prepared from C2C12 cultured in growth medium (GM) or differentiation medium
(DM) (24 h from the induction of differentiation, the point at which MyoG is activated), after treatment with Ezh1 (oligo no. 2) and Ezh2 (oligo no. 2)
small interfering RNA (siRNA), using MyoD antibody at the MyoG promoter and muscle creatine kinase (mCK) enhancer in (A) and RNA polymerase II (RNA
Pol II) and H3K4me3 antibodies at different regulatory regions of MyoG gene in (B), as represented at the top of this panel. The precipitated DNA
fragments were subjected to real-time PCR. Levels of H3K4me3 were normalised to histone H3 density. The values, shown as percentage of the input,
represent the mean of three independent experiments. The mock was less than 0.01%. Error bars represent standard deviation.
Stojic et al. Epigenetics & Chromatin 2011, 4:16
http://www.epigeneticsandchromatin.com/content/4/1/16
Page 12 of 18
H3K27/H3S28 methyl/phospho switch mechanism is the
basis of PRC2-Ezh2 target gene activation during
myogenic differentiation
If PRC2-Ezh1 is required for the correct timing of MyoG
transcriptional activation, removal of PRC2-Ezh2 from
this gene would be necessary to guarantee its activation.
One way of doing this would be to reduce intracellular
PcG levels. In regard to this, Juan et al. [14] provided
evidence that miR-214 regulates Ezh2 protein levels in
skeletal muscle and ES cells. Recent studies raise inter-
esting questions concerning the assumption that PcG
derepression must be accompanied by the loss of the
H3K27me3 repressive mark. Seenundun and coworkers
[41] showed that the histone demethylase UTX is tar-
geted to muscle-specific genes by the transcriptional
activator Six4 to mediate removal of the repressive
H3K27me3 mark during myogenesis. Recent reports
suggest that demethylation of H3K27 may not be the
only mechanism for derepression of PcG target genes
[20,21]. A novel mechanism regulating PcG displace-
ment from chromatin has been identified, in which
phosphorylation of H3S28, via mitogen and stress-acti-
vated kinases Msk1 and 2, is able to neutralise the
H3K27me3 repressive mark to result in PRC2 removal
and gene activation [20,21]. Our data show that a simi-
lar mechanism appears to operate in differentiating
myoblasts, in which Msk1 regulates a H3K27/H3S28
methyl/phospho switch to allow removal of the PRC2-
Ezh2 complex and muscle gene activation (Figure 3).
Notably, our in vitro experiments indicate that the
Msk1-methyl/phospho switch pathway is specific to the
PRC2-Ezh2 complex, while it appears that PRC2-Ezh1 is
not regulated by this mechanism (Figure 4). Our ChIP
analysis shows that the H3K27me3 mark is not alterna-
tive to H3S28ph and we can detect them independently.
The in vivo presence of a phospho group at H3S28 may
interfere with epitope recognition of H3K27me3 antibo-
dies, raising potential concerns about the interpretation
of the existing H3K27me3 ChIP genome-wide database
[11]. In our ChIP experiments we did not encounter
this problem as H3K27me3 was efficiently detected,
even in the presence of adjacent H3S28ph mark. Pre-
vious studies suggest that PRC2 function is required
during S-phase to guarantee maintenance of silenced
state [6]. A recent genome-wide analysis of histone
modifications performed in C2C12 myotubes revealed
that the H3K27me3 mark on repressed non-muscle
genes is not associated with PRC2, but with PRC1 com-
plexes [42]. Thus, the function of the PRC2 complex in
post-mitotic myotubes may not be linked to the mainte-
nance of the H3K27me3 mark. Indeed, our data suggest
that the PRC2-Ezh1 complex, and in particular the Ezh1
subunit, is required for proper MyoG activation when
H3K27me3 mark is not removed, suggesting that Ezh1
function is linked to promoter setting of terminally dif-
ferentiating cells. Future experiments will be required to
test the hypothesis that while some genes are perma-
nently inactive and do not require PRC2-Ezh2 activity
once cells have stopped proliferating, other genes
remain active and maintain their competence to resi-
lence by using chromatin bound PRC2-Ezh1, as a secur-
ity measure.
Conclusions
Our work addresses the role of PRC2 complexes during
skeletal muscle cell differentiation.
We report that two different PRC2 complexes, PRC2-
Ezh2 and PRC2-Ezh1, are differentially associated with
muscle gene regulatory regions and play distinct roles in
the terminal differentiation process. We show that as
Ezh2 is removed from MyoG and mCK, high levels of
Ezh1 persist in differentiating muscle cells and PRC2-
Ezh1 is recruited at MyoG, a step that is essential for
activation of the early myogenic program. These events
are required for regulation of the correct timing of
MyoG transcriptional activation, and loss of Ezh1 affects
recruitment of the MyoD transcription factor on its pro-
moter in post-mitotic myotubes. Further, we report that
Msk1-signalling controls H3S28ph and is involved in
the specific displacement of PRC2-Ezh2 from muscle
regulatory regions, triggering muscle gene activation and
thereby muscle cell terminal differentiation. Consistent
with its role involving MyoG transcriptional activation,
we show that the PRC2-Ezh1 complex is insensitive to
the H3S28ph activation mark. Thus, our study reveals a
novel important layer of PcG-mediated epigenetic regu-
lation of skeletal muscle cell differentiation, in which
the coordinated different dynamics and chromatin-regu-
lated switch between PRC2-Ezh2 and PRC2-Ezh1 com-
plexes are required to initiate the transition from
myoblast to myotube transcriptional programs. Notably,
our data suggest a novel and unexpected role for PRC2-
Ezh1 in promoter setting. Further, based on published
data concerning MyoG regulation in muscle fibres, we
speculate that PRC2-Ezh1 may be required for subse-
quent developmentally regulated resilencing of MyoG
and perhaps other skeletal muscle genes. Our study pro-
vides new epigenetic insights into the process of term-
inal differentiation, in which the regulated and
coordinated chromatin dynamics of two PRC2 com-
plexes is required for the correct timing of muscle gene
activation and thereby muscle differentiation.
Methods
Cell lines and reagents
C2C12 mouse myoblasts cells (ATCC, Manassas, VA,
USA) were cultured in Dulbecco’s modified Eagle med-
ium (DMEM) supplemented with penicillin/
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streptomycin and 10% fetal bovine serum (FBS) (Euro-
clone, Devon, UK). Differentiation was induced when
cells reached approximately 80% confluency using
DMEM containing ITS media supplement (Sigma, St
Louis, MO, USA) or 2% horse serum (HS) (Euroclone).
Human primary myoblasts from healthy donors were
obtained from the Telethon BioBank (Neuromuscular
Diseases and Neuroimmunology Unit, Muscle Cell Biol-
ogy Laboratory, C Besta Neurological Institute). The cell
lines were cultured in DMEM supplemented with 20%
FBS (Lonza, Basel, Switzerland), insulin 10 mg/ml,
human fibroblast growth factor (hFGF) 25 ng/ml,
human epidermal growth factor (hEGF) 10 ng/ml (pro-
liferating medium), and then induced to differentiate by
means of DMEM supplemented with 2% HS (differen-
tiating medium). H89 (Alexis Corporation, Farmingdale,
NY, USA) was replaced every 24 h.
Satellite cell isolation and culture
Single muscle fibres were isolated by standard proce-
dures. In brief, the hind limb muscles were digested
with collagenase and single myofibres were cultured in
GM1 (DMEM supplemented with 10% HS (GIBCO,
Invitrogen, Carlsbad, CA, USA), 0.5% chick embryo
extract (MP Biomedicals, Illkirch, France), and penicil-
lin-streptomycin (GIBCO)) at 37°C in suspension for 72
h, and then plated on matrigel (Sigma, 1 mg/ml ECM
gel)-coated dishes for satellite cell culture. Then, 3 days
later, the fibres were removed and the medium replaced
with proliferation medium (GM2: 20% FBS, 10% horse
serum, 1% chick embryo extract in DMEM). After 4-5
days, the medium was replaced with differentiation
medium (DM: 2% HS and 0.5% chick embryo extract in
DMEM).
RNA isolation and quantitative real-time PCR
RNA was extracted from cells using TriReagent (Sigma)
according to the manufacturer’s instructions. cDNA
synthesis was performed using the QuantiTect reverse
transcription kit (Qiagen, Hilden, Germany). Quantita-
tive real-time PCR reactions were performed in triplicate
using QuantiTect SYBR Green master mix (Qiagen) on
a DNA Engine Opticon 2 machine (MJ Research) con-
trolled by Opticon Monitor 2 software. C(T) values
were calculated by Opticon Monitor 2 software. Gapdh,
MHCIIB and mCK primers have been previously
described [13]. The remaining primer sequences are
available upon request.
RNA interference
C2C12 cell line and satellite cells: siRNA EZH1 no. 1
(SI00997766), siRNA EZH1 no. 2 (SI00997773), siRNA
SUZ12 no. 1 (SI01438416), siRNA SUZ12 no. 2
(SI01438402), as well as negative control siRNA
(scrambled sequence not targeting mouse genome,
1027313) were purchased from Qiagen. The remaining
siRNA sequences are as follows: siRNA Ezh2 no. 1:
AAGGAAAGAACTGAAACTTA; siRNA Ezh2 no. 2:
AAGCTGAAGCCTCCATGTTTA.
Cells were transfected with HiPerfect (Qiagen) follow-
ing the manufacturer’s instructions. At 48 h after trans-
fection the cells were induced to differentiate and
collected at the indicated timepoints. All siRNAs were
used at a final concentration of 20 nM.
Human myoblasts: cells were transfected with Dhar-
maFECT (Thermo-Scientific, Waltham, Massachusetts,
USA) following the manufacturer’s instructions. At 48 h
after transfection the cells were induced to differentiate
and collected at the indicated timepoints. All siRNAs
were used at a final concentration of 6 nM (Ambion/
Applied Biosystems, USA). The siRNA sequences are
available upon request.
Cell lysis and immunoblot
Cells were harvested and washed twice with PBS. Cell
lysis of total cell extracts was performed on ice in 50
mM Tris-HCl pH 8, 125 mM NaCl, 1% NP-40, 2 mM
ethylenediaminetetra-acetic acid (EDTA), 1 mM phenyl-
methylsulfonyl fluoride (PMSF) and protease inhibitory
cocktail (Roche, Madison, WI, USA)) for 25 min. Insolu-
ble material was pelleted by centrifugation at 16000 g
for 3 min at 4°C. Protein concentration was determined
using the Bradford assay (Bio-Rad, Hercules, CA, USA).
The proteins were denatured, reduced, separated by
SDS-PAGE and transferred to nitrocellulose transfer
membrane. The membranes were blocked with 5% non-
fat dry milk in Tris-buffered saline (TBS) supplemented
with 0.1% Tween (Sigma) (TBST) and incubated with
primary antibodies overnight at 4°C. Following three
washes with TBST, membranes were incubated with the
peroxidase-conjugated secondary antibody, in TBST
with 2.5% non-fat dry milk, and immunoreactive pro-
teins were detected using Supersignal West Dura HRP
Detection Kit (Thermo-Scientific). For cytoplasmic and
nuclear extracts preparation the cells were resuspended
first in buffer A (10 mM 4-(2-hydroxyethyl)-1-pipera-
zine-ethanesulfonic acid (Hepes), pH 7.9, 10 mM KCl,
0.1 mM EDTA and 0.1 mM ethylene glycol tetra-acetic
acid (EGTA)) supplemented with protease inhibitory
cocktail (Roche), 1 mM dithiothreitol (DTT) and 1 mM
PMSF. After incubation on ice for 10 min, NP-40 was
added to a final concentration of 0.5% and the samples
were vortexed for 5 s. Nuclei were pelleted at 13,200
rpm for 10 s and the cytoplasmic proteins were col-
lected. The pellet was then washed five times with buf-
fer A and resuspended in buffer C (20 mM Hepes pH
7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, protease inhibitory cocktail (Roche) and 1 mM
Stojic et al. Epigenetics & Chromatin 2011, 4:16
http://www.epigeneticsandchromatin.com/content/4/1/16
Page 14 of 18
PMSF). After 10 min on ice, the samples were sonicated
and centrifuged at 13,200 rpm for 10 min and nuclear
proteins were collected.
Chromatin immunoprecipitation
ChIP was performed as previously described (Breiling A
and Orlando V, doi:10.1101/pdb.prot4560, with adapta-
tions) using a crosslinking time of 10 min. Antibodies
were coupled to Dynal magnetic beads (Invitrogen) by
overnight incubation at 4°C. The following day, chroma-
tin was added to antibody-bead complexes and incu-
bated overnight at 4°C. The bound complexes were
washed twice in Low Salt Solution, twice in High Salt
Solution, once in LiCl and once in Tris/EDTA (TE) buf-
fer. DNA was extracted from beads by standard phenol/
chloroform extraction, precipitated and resuspended in
30 μl TE. To quantify the results, quantitative (q)PCR
reactions were performed in triplicate (precipitated
DNA samples as well as serially diluted input DNA)
using QuantiTect SYBR Green master mix (Qiagen) on
a DNA Engine Opticon 2 machine (MJ Research) con-
trolled by Opticon Monitor 2 software. C(T) values
were calculated by Opticon Monitor 2 software. To cal-
culate relative enrichment the signal from the control
immunoprecipitation experiment (Mock) was subtracted
from that observed with the antibody of interest. Myo-
blasts values (GM) were set as 1 and values from differ-
entiated cells in DM with or without inhibitor display
relative enrichment or reduction to those observed in
GM. ChIP primers are available upon request.
Antibodies
For immunoblot: EZH2 (3147) was from Cell Signaling
(Danvers, MA, USA). SUZ12 (46264), MyoG (12732),
and MHCIIB (2064) were from Santa Cruz (Santa Cruz,
CA, USA). b-Tubulin (T0198) was from Sigma. mCK
antibody was kindly provided by Hidenori Ito (Aichi
Human Service Center, Kasugai, Aichi, Japan). Ezh1 and
EED antibodies were previously characterised ([7], [23]).
For ChIP: H3K4me3 (8580), RNA polymerase II (5408)
and SUZ12 (12073) were from Abcam (Cambridge, UK)
while Ezh2 (07-400), H3K27me3 (07-449), H3S28ph
(07-145), H3S10ph (05-817) and Acetyl H3 (06-599)
were purchased from Millipore (Billerica, Massachusetts,
USA). MSK1 (9392, 25417) and MyoD (760) were from
Santa Cruz.
Size exclusion chromatography
Size exclusion chromatography was performed using
C2C12 cell nuclear extracts on a Superose 6 PC 3.2/30
gel filtration column (GE Healthcare, Little Chalfont,
UK) using an AEKTA purifier system (GE Healthcare)
in IP (300) buffer (50 mM Tris-HCl at pH 7.5, 300 mM
NaCl, 5% glycerol, 0.2% Igepal (Sigma), Aprotinin,
Leupeptin, 100 mM PMSF, 1 mM DTT). Immunodeple-
tion was performed as described [43]. Briefly, protein
extracts were subjected to five serial depletions within
24 h at 4°C using the AC22 EZH2 monoclonal antibody
[44] precoupled to Protein-A beads.
Histone tail peptides
Histone H3 peptides were synthesised in unmodified
and modified form using Fmoc (N-(9-fluorenyl)methox-
ycarbonyl)-based solid-phase synthesis. Peptides used for
kinase assays corresponded to amino acids 21-33 of H3
containing an artificial Y at the C-terminus: H3 unmodi-
fied, ATKAARKSAPATGY; H3K27me3, ATKAARK
(me3)SAPATGY; H3S28ph, ATKAARKS(ph)APATGY.
Peptides used for precipitation experiments corre-
sponded to amino acids 1-40 of H3 and contained a C-
terminal non-native YCK sequence with the lysine bioti-
nylated at the e-amino group: H3 unmodified, ARTKQ-
TARKSTGGKAPRKQLATKAARKSAPATGGVKKPHR-
YCK (biotin); H3K27me3, ARTKQTARKSTGG-
KAPRKQLATKAARK(me3)SAPATGGVKKPHR-YCK
(biotin); H3K27me3S28ph, ARTKQTARKSTGG-
KAPRKQLATKAARK(me3)S(ph)APATGGVKKPHR-
YCK (biotin).
In vitro peptide kinase assay
Recombinant MSK1 (Millipore) was used to phosphory-
late H3 histone tail peptides (21-33). Kinase assays were
performed according to the manufacturer’s protocol by
incubating 15 ng of MSK1 with 1 μg of peptide for 30
min at 30°C. The reaction was stopped by adding 0.5%
phosphoric acid, spotted on P81 paper and washed
three times with 0.5% phosphoric acid and once with
acetone. Filter circles were air dried and counted in a
scintillation counter.
Peptide affinity purification
For preparation of nuclear extracts, cells were lysed in
buffer A (10 mM Hepes-KOH pH 7.8, 60 mM KCl, 1
mM EDTA, 1 mM DTT, protease inhibitor cocktail
(Roche), 0.075% NP-40). After incubation on ice for 15
min, nuclei were pelleted and washed once with buffer
A without NP-40. The nuclear pellet was suspended in
buffer B (20 mM Tris pH 8.0, 300 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 25% glycerol, 1 mM DTT, pro-
tease inhibitor cocktail, PhosSTOP (Roche)) and soni-
cated on ice in a Branson Sonifier (duty cycle 20%,
output 7.5). Extract was left on ice for 30 min before
centrifugation for 15 min at 16,000 g. The supernatant
was supplemented with 0.1% Triton X-100 and used for
precipitation experiments.
For H3 peptide precipitation experiments, 10 μg of
biotinylated histone peptides (1-40) were coupled to 50
μl streptavidin-coated paramagnetic beads in PBS/bovine
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serum albumin (BSA) (1 mg/ml) for 4 h at 4°C. Beads
were washed three times with PD150 (10 mM Tris pH
7.5, 150 mM NaCl, 0.1% Triton X-100, 20% glycerol, 1
mM DTT, protease inhibitor cocktail, PhosSTOP) to
remove unbound peptides. Peptide-bound beads were
incubated with nuclear extract for 2 h and washed four
times with PD300. Bound proteins were eluted with
SDS sample buffer, separated by SDS-PAGE and ana-
lysed by immunoblotting.
Immunofluorescence
Cells were grown on coverslips, washed in PBS, fixed in
3.7% formaldehyde/PBS (15 min, 4°C) and permeabilised
in 0.2% Triton X-100/PBS (5 min, 4°C). The coverslips
were then washed in PBS, and blocked with 3% low-fat
milk/PBS for 1 h at room temperature. Following over-
night incubation with primary antibodies at 4°C, the
coverslips were washed and incubated with secondary
antibodies (Molecular Probes, Eugene, OR, USA) for 60
min at 37°C, and then washed again and counterstained
with 4’,6-diamidino-2-phenylindole (DAPI; 1 μg/μl, Vec-
tashield, Vector Laboratories Inc., Burlingame, CA,
USA)). Pictures were captured using epifluorescence
microscopy (Leica DM6000B) using Leica Application
Suite software.
Fluorescence-activated cell sorting (FACS) analysis
C2C12 myoblasts were cultured in growing conditions
and collected at 24 h, 48 h, 72 h and 96 h after plating.
Cells were divided in aliquots of 1.2 × 106 cells per
tube, washed with cold PBS 1 ×, fixed by 70% cold etha-
nol and incubated for 30 min on ice. After incubation,
cells were washed with PBS 1 ×, resuspended in 0.5 ml
of PBS 1 ×/RNase A (100 μg/ml) and incubated at 37°C
for 30 min. Finally, propidium iodide (20 μg/ml) was
added and the cells were incubated in the dark for 30
min at 4°C. The samples were then analyzed for the cell
cycle profile and the cell death profile using a Becton
Dickinson Instrument.
Additional material
Additional file 1: Dynamics of PRC2 components in human skeletal
muscle and satellite cells. (A) Expression levels of hEzh2, hEzh1 and
hSuz12 were measured by real-time PCR in human myoblasts grown in
growth medium (GM) or differentiation medium (DM) (1 day, 4 days and
8 days after induction of differentiation). The transcription levels were
normalised to hGapdh expression and represent the mean of three
independent experiments ± SD. Fold enrichment was calculated in
comparison to myoblasts in GM. (B) Expression levels of Ezh2, Ezh1 and
Suz12 were measured by real-time PCR in myofibre-derived satellite cells
grown in GM or DM (72 h after differentiation induction). Pax7 was used
as a control for these cells and myogenin (MyoG) and myosin heavy chain
IIB (MHCIIB) were used as muscle differentiation controls. The
transcription levels were normalised to Gapdh expression and represent
the mean of three independent experiments ± SD. Fold enrichment was
calculated in comparison to myoblasts in GM.
Additional file 2: C2C12-H89 treatment impairs muscle gene
activation. (A) Schematic representation of the design of Msk1 inhibitor
H89 treatment used in this study. (B) The effect of H89 treatment (5 μM
and 10 μM) on C2C12 muscle cell differentiation was analysed in
differentiation medium (DM) (48 h after treatment) by phase-contrast
microscopy. (C) Expression levels of myogenin (MyoG) and muscle creatine
kinase (mCK) were measured by real-time PCR in C2C12 myoblasts
cultured in growth medium (GM) or DM (48 h after differentiation
induction) with or without Msk1 inhibitor H89 (5 μM). Transcription levels
were normalised to Gapdh expression. The data are shown as the
average of three independent experiments, with error bars representing
standard deviation. Fold enrichment was calculated in comparison to
myoblasts in GM. (D) Immunoblot of MyoG and mCK from whole cell
extracts of C2C12 myoblasts cultured in GM or DM (48 h after
differentiation induction) with or without H89 (5 μM). b-Tubulin was
used as a loading control. (E) Chromatin immunoprecipitation (ChIP)
analyses of MyoG promoter, mCK enhancer and mCK promoter were
performed on chromatin prepared from C2C12 cells cultured in GM or
DM for 48 h after induction of differentiation, using histone H3
phosphorylation at serine 10 (H3S10ph) antibody. Levels of H3S10ph
were normalised to histone H3 density. The precipitated DNA fragments
were subjected to real-time PCR analysis. ChIP values are presented as
relative enrichments to myoblasts. The values represent the mean ± SD
of three independent experiments.
Additional file 3: Efficiency of Ezh1 and Ezh2 small interfering RNA
(siRNA) in C2C12 cells. (A) Myoblasts were transfected with non-
targeting siRNA (Nc = negative control) or siRNA against Ezh1 (siEzh1 no.
1 and siEzh1 no. 2), and the efficiency of siRNA was tested by real-time
PCR in growth medium (GM) and in differentiation medium (DM) (48 h
after differentiation induction). The transcription levels were normalised
to Gapdh expression and represented as the average of three
independent experiments ± SD. Fold enrichment was calculated in
comparison to the negative control siRNA in GM. (B)
Immunofluorescence for Ezh1 performed after delivery of siRNA into
cells. Note the weak labelling in a high number of cells treated with
Ezh1 siRNA (no. 2). Scale bar = 50 μm. (C) Myoblasts were transfected
with non-targeting siRNA (Nc = negative control) or siRNA against Ezh2
(siEzh2 no. 1 and siEzh2 no. 2) and the efficiency of siRNA was tested by
real-time PCR in GM and in DM (48 h after differentiation induction). The
transcription levels were normalised to Gapdh expression and
represented as the average of three independent experiments ± SD. Fold
enrichment was calculated in comparison to the negative control siRNA
in GM. (D) Immunofluorescence of Ezh2 48 h post transfection with
siRNA (oligo no. 2). Scale bar = 100 μm.
Additional file 4: Ezh1-depleted human myoblasts and satellite cells
show a delay in myogenin (MyoG) transcriptional activation. (A)
Human myoblasts were transfected with either non-targeting small
interfering RNA (siRNA) (Nc = negative control) or siRNA against Ezh1.
The effect of siRNA on cell morphology was analysed in growth medium
(GM) (48 h after transfection) and in differentiation medium (DM) (2 and
4 days after differentiation induction) by phase-contrast microscopy. (B)
The efficiency of siRNA for Ezh1 and the expression levels of MyoG were
tested by real-time PCR in GM and in DM (2 days and 4 days after
differentiation induction), in human myoblasts depleted for Ezh1. The
transcription levels were normalised to Gapdh expression and are
represented as the average of three independent experiments ± SD. Fold
enrichment was calculated in comparison to negative control siRNA in
GM. (C) Myofibre-derived satellite cells were transfected with non-
targeting siRNA (Nc = negative control) or siRNA against Ezh1 (no. 1).
The effect of siRNA on cell morphology was analysed in GM (48 h after
transfection) and in DM (2 days after differentiation induction) by phase-
contrast microscopy. (D) The efficiency of siRNA for Ezh1 and the
expression levels of MyoG were tested by real-time PCR in GM and in
DM (48 h after differentiation induction) in myofibre-derived satellite cells
depleted for Ezh1 (oligo no. 1). The transcription levels were normalised
to Gapdh expression. Fold enrichment was calculated as a percentage
(%) of the negative control siRNA in GM.
Additional file 5: Suz12 small interfering RNA (siRNA) affects
myogenin (MyoG) transcriptional activation in human myoblasts
and in satellite cells. (A) Human myoblasts were transfected either with
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non-targeting siRNA (Nc = negative control) or siRNA against Suz12. The
effect of siRNA on cell morphology was analysed in growth medium
(GM) (48 h after transfection) and in differentiation medium (DM) (2 and
4 days after differentiation induction) by phase-contrast microscopy. (B)
The efficiency of siRNA for Suz12 and the expression levels of MyoG were
tested by real-time PCR in GM and in DM (2 days and 4 days after
differentiation induction), in human myoblasts depleted for Suz12. The
transcription levels were normalised to Gapdh expression and are
represented as the average of three independent experiments ± SD. Fold
enrichment was calculated in comparison to the negative control siRNA
in GM. (C) Myofibre-derived satellite cells were transfected with either
non-targeting siRNA (Nc = negative control) or siRNA against Suz12 (no.
1). The effect of siRNA on cell morphology was analysed in GM (48 h
after transfection) and in DM (2 days after differentiation induction) by
phase-contrast microscopy. (D) The efficiency of siRNA for Suz12 and the
expression levels of MyoG were tested by real-time PCR in GM and in
DM (2 days after differentiation induction) in myofibre-derived satellite
cells depleted for Suz12. The transcription levels were normalised to
Gapdh expression. Fold enrichment was calculated in comparison to the
negative control siRNA in GM.
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